AIMD on XNAS, Technology, Ainos, Inc., job postings
Measures activity, not value. Not investment advice.
Revenue jumped 479% to $654K while a delisting notice arrived and the net loss hit $13.4M.
BadDebt of $13.8M against $661K cash on the balance sheet
Written by AI from the data on this page, 22 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
Ainos Inc is a dual-platform company advancing artificial intelligence based smelltech technologies and immune therapeutics. Its primary strategic focus is the commercialization of its proprietary scent digitization platform, AI Nose, while the company also continue to develop therapeutic assets based on its low-dose oral interferon program, VELDONA. Its core technology platform, AI Nose, is an AI-based electronic olfaction system that integrates gas sensor arrays with proprietary artificial intelligence models, which it refers to as a smell language model (SLM), to digitize scent and volatile organic compound (VOC) signals into Smell ID, a machine-readable data format.
expected around 29 Mar 2027 (an estimate: a year ago it reported on 30 Mar 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $643K, net loss $1.9M.
31 Dec 2021RevenueNet incomeNet losstallest bar $7.8M30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
$643K
-$1.9M
30 Jun 2026
$152
-$4.6M
31 Mar 2026
$161
-$2.5M
31 Dec 2025
$11K
-$4.5M
30 Sep 2025
$2K
-$2.9M
30 Jun 2025
$5K
-$4.1M
31 Mar 2025
$106K
-$3.3M
31 Dec 2024
$0
-$4.7M
30 Sep 2024
$0
-$3.7M
30 Jun 2024
$0
-$3.2M
31 Mar 2024
$21K
-$3.3M
31 Dec 2023
$20K
-$5.9M
30 Sep 2023
$24K
-$3.0M
30 Jun 2023
$29K
-$2.3M
31 Mar 2023
$49K
-$2.5M
31 Dec 2022
$1.0M
-$2.1M
30 Sep 2022
$1.8M
-$7.8M
30 Jun 2022
$637K
-$2.0M
31 Mar 2022
$87K
-$2.1M
31 Dec 2021
$26K
-$1.4M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
$654K
$113K
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
+479%
+8.0%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
-$13.4M
-$15.0M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
-$2.07
-$2.93
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
83.3%
82.7%
45.5%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
–
–
2.5%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
–
–
0.6%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
-228%
3.0%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
–
–
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$661K
$1.1M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
$13.8M
$11.0M
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
$13.2M
$9.9M
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
8.0
0.08
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
$0.23
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
loss
26.2
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
13.6
2.7
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
33.7
3.1
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
5.2
3.3
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
2.7%
205K shares held by 13F filers (30 Sep 2026) of 7.6M outstanding (16 Nov 2026)
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
0.5%
38K shares sold short (30 Oct 2026) of 7.6M outstanding (16 Nov 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
1.4
38K shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
-20%
47K shares sold short in the report before, 38K on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
40%
40% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 36%
News iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
18
18 articles in the last 7 days; its usual week has 1 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
18×
18 articles in the last 7 days; its usual week has 1.
Price $1.18 on 20 Nov 2026, -38% over 12 months (12-month range $0.47 to $3.16)
Sharp change
8-K and other filings
Insider net buying (open market). Insiders sold a net $469K in the last 12 months (the 12 months before: -$191K).Revenue per quarter. Revenue $643K in the latest quarter, +29567% on a year earlier.Capital spending per quarter. Capital spending $6K in the latest quarter.Institutional holders (13F filers). 15 13F filers reported holding it in the latest 13F quarter, +25% on a year earlier.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, federal obligations, lobbying spend, workers in warn layoff notices.
Quarter ended 31 Dec 2021: $26K, +3743% on a year earlier; public on 22 Mar 2022
Quarter ended 31 Mar 2022: $87K, +4011% on a year earlier; public on 17 May 2022
Quarter ended 30 Jun 2022: $637K, +214% on a year earlier; public on 16 Aug 2022
Quarter ended 30 Sep 2022: $1.8M, +384% on a year earlier; public on 15 Nov 2022
Quarter ended 31 Dec 2022: $1.0M, +3832% on a year earlier; public on 4 Apr 2023
Quarter ended 31 Mar 2023: $49K, -44% on a year earlier; public on 13 May 2023
Quarter ended 30 Jun 2023: $29K, -96% on a year earlier; public on 12 Aug 2023
Quarter ended 30 Sep 2023: $24K, -99% on a year earlier; public on 10 Nov 2023
Quarter ended 31 Dec 2023: $20K, -98% on a year earlier; public on 9 Mar 2024
Quarter ended 31 Mar 2024: $21K, -58% on a year earlier; public on 14 May 2024
Quarter ended 30 Jun 2024: $0, -100% on a year earlier; public on 6 Aug 2024
Quarter ended 30 Sep 2024: $0, -100% on a year earlier; public on 7 Nov 2024
Quarter ended 31 Dec 2024: $0, -100% on a year earlier; public on 8 Mar 2025
Quarter ended 31 Mar 2025: $106K, +412% on a year earlier; public on 15 May 2025
Quarter ended 30 Jun 2025: $5K; public on 14 Aug 2025
Quarter ended 30 Sep 2025: $2K; public on 14 Nov 2025
Quarter ended 31 Dec 2025: $11K; public on 31 Mar 2026
Quarter ended 31 Mar 2026: $161, -100% on a year earlier; public on 14 May 2026
Quarter ended 30 Jun 2026: $152, -97% on a year earlier; public on 4 Aug 2026
Quarter ended 30 Sep 2026: $643K, +29567% on a year earlier; public on 17 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $102K; public on 22 Mar 2022
Quarter ended 31 Mar 2022: $136K; public on 13 May 2023
Quarter ended 31 Mar 2023: $72K, -47% on a year earlier; public on 13 May 2023
Quarter ended 30 Sep 2023: $37K; public on 10 Nov 2023
Quarter ended 31 Mar 2024: $4K, -94% on a year earlier; public on 14 May 2024
Quarter ended 30 Jun 2024: $6K; public on 6 Aug 2024
Quarter ended 30 Sep 2024: $10K, -72% on a year earlier; public on 7 Nov 2024
Quarter ended 31 Dec 2024: $908; public on 8 Mar 2025
Quarter ended 31 Mar 2025: $34K, +660% on a year earlier; public on 15 May 2025
Quarter ended 30 Sep 2025: $10K, -0.1% on a year earlier; public on 14 Nov 2025
Quarter ended 31 Mar 2026: $9K, -75% on a year earlier; public on 14 May 2026
Quarter ended 30 Jun 2026: $6K; public on 4 Aug 2026
Institutional holders (13F filers)
30 Sep 2022 report: 7; public on 14 Nov 2022
31 Dec 2022 report: 6; public on 14 Feb 2023
31 Mar 2023 report: 8; public on 15 May 2023
30 Jun 2023 report: 5; public on 14 Aug 2023
30 Sep 2023 report: 15; public on 14 Nov 2023
31 Dec 2023 report: 5; public on 14 Feb 2024
31 Mar 2024 report: 9; public on 15 May 2024
30 Jun 2024 report: 9; public on 14 Aug 2024
30 Sep 2024 report: 8; public on 14 Nov 2024
31 Dec 2024 report: 8; public on 14 Feb 2025
31 Mar 2025 report: 12; public on 15 May 2025
30 Jun 2025 report: 7; public on 14 Aug 2025
30 Sep 2025 report: 12; public on 14 Nov 2025
31 Dec 2025 report: 14; public on 17 Feb 2026
31 Mar 2026 report: 12; public on 15 May 2026
30 Jun 2026 report: 14; public on 14 Aug 2026
30 Sep 2026 report: 15; public on 16 Nov 2026
What is unusual now
Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is gross profit, quarter at $536K (30 Sep 2026), 229274% below its normal quarter of -$234; higher than 98% of its own history.
had 634K shares sold short in the 15 Jan 2025 report, 17× the same report last year.
Same report last year: 37K; its normal report is 118K.
See the evidence
This period
634K (the 15 Jan 2025 report)
Normal report (median of 24 earlier)
118K
Typical spread (median absolute deviation)
64K
How far from its usual level
+5.5
Same report last year
37K
History used
1,328 days
the 15 Jan 2025 report24 earlier reportsnormal: 118K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Showing the newest 40 of 132 entries; narrow the window or the kind of data to see older ones.
Not listed: 122 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0001014763
Ticker
AIMD
Domain
ainos.com
Hq location
TX|HOUSTON|77056 (1 unverified)
Lobbying client
amarillo biosciences
Name
Ainos, Inc., AMARILLO BIOSCIENCES INC, EX-21.1, ex21-1.htm and 3 more
Federal lobbying disclosures (LDA)2 records, 56 data points31 Dec 2006 to 31 Mar 2014
SEC Form 13F institutional holdings153 data points30 Sep 2022 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)161 records30 Mar 2016 to 20 Nov 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)1001 data points31 Dec 2009 to 16 Nov 2026
SEC Form 4 insider transactions257 records, 960 data points26 Feb 2016 to 9 Jun 2026
FINRA short interest (twice monthly)389 data points28 May 2021 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)2130 data points9 Aug 2022 to 20 Nov 2026